Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Hoofddorp – page 153

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hoofddorp at a glance
1 940
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 940 trials in Hoofddorp

Open in trial search

Attention deficit hyperactivity disorder

Not recruiting

Study on the Safety and Effectiveness of Guanfacine Hydrochloride and Atomoxetine Hydrochloride for Children and Adolescents with ADHD Aged 6 to 17 Years

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Guanfacine
  • Sponsor:Takeda Development Center Americas Inc.

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

High-grade B-cell lymphoma

Not recruiting

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Coronary artery disease

Not recruiting

Study on O15-Water for Diagnosing Coronary Artery Disease in Patients Using PET Imaging During Stress and Rest Conditions

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:O15-WATER
  • Sponsor:MedTrace Pharma A/S

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Portal hypertension

Not recruiting

Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hyperoxaluria

Not recruiting

Study on Lumasiran for Patients with Advanced Primary Hyperoxaluria Type 1

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Lumasiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Bial R&D Investments S.A.

COVID-19+2

Not recruiting

Study on Everolimus and Mycophenolate Mofetil for Improving COVID-19 Vaccine Response in Kidney Transplant Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Universitair Medisch Centrum Groningen

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatments
  • Urothelial Cancer Therapies
  • Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

  • B-Cell Lymphoma Treatments
  • Myelofibrosis Therapies
  • Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

  • Weight Management Interventions
  • Surgical Techniques
  • Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.